Zobrazeno 1 - 10 of 14 pro vyhledávání: '"JINGJUE MAO"'
1
Association between baseline Controlling Nutritional Status score and clinical outcomes of patients with multiple myeloma
Autor: Jing Wang, Yan Lu, Jingjue Mao, Jun Xia, Hongfeng Guo, Xin Zhou
Publikováno v: Cancer biomarkers : section A of Disease markers. 32(1)
BACKGROUND: The Controlling Nutritional Status (CONUT) score, a novel immuno-nutritional index, was reported as a predictor of overall survival (OS) in some tumors. OBJECTIVE: We aimed to investigate the association between baseline CONUT Score and c
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb3f7ef3e0832b079d010cd1a2a376b7
https://pubmed.ncbi.nlm.nih.gov/34092619
Zobrazit plný text záznamu
2
Impact of Extended Treatment Interval on the Prognosis of Multiple Myeloma Patients: A Retrospective Study
Autor: Chao Sun, Jingjue Mao, Jian-Nan Ye, Ke-Wa Ma, Xin Zhou
Publikováno v: Oncology research and treatment. 43(11)
Introduction: Recently, treatment with proteasome inhibitors and immunomodulators has improved the prognosis of multiple myeloma (MM). However, in a complex real-world situation, the patient’s ability to undergo regular and timely treatment as pres
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7befadfbadf57f5300dd0957b711219
https://pubmed.ncbi.nlm.nih.gov/33045715
Zobrazit plný text záznamu
3
Real-world outcome and healthcare costs of relapsed or refractory multiple myeloma: A retrospective analysis from the Chinese experience
Autor: Feng Cheng, Xifeng Qian, Jingjue Mao, Xin Zhou, Jun Xia, Hongfeng Guo
Publikováno v: Hematology. 21:280-286
Our aim was to retrospectively investigate the real-world outcome and healthcare costs associated with the treatment of patients with relapsed or refractory multiple myeloma (RRMM) in a Chinese single center.A retrospective study was conducted for 93
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f50a01554ee38adef63ae458a67ef785
https://doi.org/10.1080/10245332.2015.1122259
Zobrazit plný text záznamu
4
Evaluation of neutrophil-to-lymphocyte ratio in newly diagnosed patients receiving borte- zomib-based therapy for multiple myeloma
Autor: Jian-Wei Zhu, Jingjue Mao, Xin Zhou, Jun Xia, Feng Cheng, Hongfeng Guo, Jing Wang
Publikováno v: Cancer biomarkers : section A of Disease markers. 22(1)
BACKGROUND The neutrophil-to-lymphocyte ratio (NLR) at diagnosis has been identified as an independent prognostic marker in several malignancies. Recently, a few studies have reported that an elevated pretreatment NLR is associated with poor survival
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e43afa0d3c5277d2da9208531c4eace
https://pubmed.ncbi.nlm.nih.gov/29562497
Zobrazit plný text záznamu
6
Short-course bortezomib-based retreatment for patients with multiple myeloma who had received bortezomib-thalidomide-dexamethasone (VTD) as an initial therapy: A single-center case series
Autor: Xin Zhou, Feng Cheng, Yuanxin Zhu, Jingjue Mao, Hongfeng Guo, Jing Wang, Yuanqiang Jiang, Heng Chen
Publikováno v: Experimental and Therapeutic Medicine
Studies have shown that the bortezomib-based retreatment of patients with multiple myeloma (MM) may prolong control of the disease. The optimal duration of bortezomib-based retreatment in relapsed or refractory MM is unknown. The present retrospectiv
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4a992ecf8ba7b68c897853da0e48d7b
http://europepmc.org/articles/PMC3964925
Zobrazit plný text záznamu
7
Bortezomib plus intermediate-dose dexamethasone and thalidomide in elderly untreated patients with multiple myeloma: A Chinese experience
Autor: Xifeng Qian, Xin Zhou, Jun Xia, Hong-Li Sun, Feng Chen, Yuanqiang Jiang, Mize Lu, Heng Chen, Yun-Feng Shen, Jingjue Mao, Yun Zhuang, Guohua Yang, Chao Sun, Hongfeng Guo
Publikováno v: American Journal of Hematology. 85:499-501
Bortezomib has proven to be active in patients with multiple myeloma (MM), including elderly patients. The aim of this study was to evaluate the efficacy and toxicity of bortezomib in combination with intermediate-dose dexamethasone (Dex) and thalido
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf87c72932a2dc1572f46dd8967424b4
https://doi.org/10.1002/ajh.21734
Zobrazit plný text záznamu
8
Rapid Fatal Pulmonary Complications in a Chinese Patient After Bortezomib Treatment for ALK-Negative Anaplastic Large-Cell Lymphoma
Autor: Xin Zhou, Jingjue Mao, Chao Sun, Jing Wang, Hongfeng Guo
Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 10:152-154
Bortezomib, a reversible proteasome inhibitor, is used for the treatment of hematologic malignancies. Common adverse events with bortezomib include gastrointestinal symptoms, thrombocytopenia, and neuropathy, whereas severe pulmonary complications ha
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5b6dd6a33af5cf0b0f8e776cb556a72
https://doi.org/10.3816/clml.2010.n.023
Zobrazit plný text záznamu
10
Akademický článek
Restoration of Sensitivity to Bortezomib-Based Therapy in an Elderly Patient With Multiple Extramedullary Relapses of Multiple Myeloma in Different Locations.
Autor: Chao Sun, Xin Zhou, Jing Wang, Jingjue Mao, Hongfeng Guo
Publikováno v: European Journal of Clinical & Medical Oncology; 2012, Vol. 4 Issue 2, p91-94, 4p, 2 Color Photographs, 2 Charts
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje